People v. Cancer

People of lower socioeconomic status face higher cancer death rates than their counterparts. African American men suffer the highest cancer incidence rate of any racial or ethnic group. But these gaps in cancer care can be addressed through policy. What does the case of Medicaid expansion reveal about cancer disparities in America? And what will … Continue reading People v. Cancer

Q&A

Adamson spoke with Matthew Ong, a reporter with The Cancer Letter Before 2019, Blythe Adamson, a senior quantitative scientist at Flatiron Health, had never attended an annual meeting of the American Society of Clinical Oncology. In the shower, sometime in November 2018, Adamson came up with an idea for future research: “I think we should … Continue reading Q&A

Press: ACA Medicaid expansion eliminated racial disparities in timely cancer treatment

This post has a summary of press coverage about results from a research study from Flatiron Health and Yale, following the Plenary Session presentation at ASCO 2019. We learned that Affordable Care Act (ACA) Medicaid expansion was associated with reduction in racial disparity in timely treatment of advanced cancer. Results were reported in the The … Continue reading Press: ACA Medicaid expansion eliminated racial disparities in timely cancer treatment

Incentivizing health-promoting behaviors

A new comprehensive landscape analysis of Medicaid health behavior incentive programs gathers together many challenges and potential solutions in the latest issue of Health Affairs. In 2017-2018 the team interviewed 80 key-informant stakeholders and searched the literature. The most common incentive type offered by programs was gift cards or vouchers, including cash, Visa gift cards, specific venue … Continue reading Incentivizing health-promoting behaviors

data|evidence|policy|practice

The Irish Department of Health (DoH) is in the process of developing a national biosimilar medicines policy which aims to increase biosimilar use by creating a robust framework where biologicals and biosimilars can be used safely, cost-effectively, and confidently in the health service. In this example from an Irish teaching hospital, the introduction of the biosimilar first to new patients, along with a switching study executed in parallel, helped to raise prescriber confidence. Continue reading data|evidence|policy|practice

Economic Impact of Comparative-Effectiveness Studies

@AcademyHealth #ARM2018 attendees: join me on Monday at 3:15 pm in room 605-606, where Anirban Basu will present our work in collaboration with the Patient Centered Outcomes Research Institute (PCORI) to quantify the potential economic impact of the findings from comparative-effectiveness research studies. Goal Our goal was to understand the potential benefits of implementing comparative-effectiveness … Continue reading Economic Impact of Comparative-Effectiveness Studies

Progress in viral suppression shifts distribution of metrics in US states

While preparing a review for the journal Current HIV/AIDS Reports, I uncovered some interesting longitudinal trends in the care cascade and heterogeneity in the progress of US states. The following visualizations describe CDC HIV surveillance data from 2010-2014. They didn’t make the cut for our review paper, and they are too beautiful and interesting to … Continue reading Progress in viral suppression shifts distribution of metrics in US states

BBC Interview

On Tuesday, April 17, the journal Nature Scientific Reports published our paper “Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.” A few hours later, a reporter from BBC World Service reached out to discuss the the results of our study. Live Interview You can listen to this clip with … Continue reading BBC Interview